CIK 0000914475
- Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330525145
- Phone
- +1 858-617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-10 | Lloyd-Smith Malcolm Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option | −1,700 | $35.99 | $61K | 21,533 |
| 2021-02-08 | ROBERTS EIRY Chief Medical Officer | Grant or award · Stock Option | +49,049 | 49,049 | ||
| 2021-02-08 | Lloyd-Smith Malcolm Chief Regulatory Officer | Grant or award · Stock Option | +35,035 | 35,035 | ||
| 2021-02-08 | Lippoldt Darin Chief Legal Officer | Grant or award · Stock Option | +45,546 | 45,546 | ||
| 2021-02-08 | Grigoriadis Dimitri E. Chief Research Officer | Grant or award · Stock Option | +42,042 | 42,042 | ||
| 2021-02-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Stock Option | +113,863 | 113,863 | ||
| 2021-02-08 | Gano Kyle Chief Business Development Off | Grant or award · Stock Option | +49,049 | 49,049 | ||
| 2021-02-08 | Cooke Julie Chief Human Resources Officer | Grant or award · Stock Option | +35,035 | 35,035 | ||
| 2021-02-08 | Bozigian Haig P. Chief Development Officer | Grant or award · Stock Option | +3,504 | 3,504 | ||
| 2021-02-08 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Stock Option | +49,049 | 49,049 | ||
| 2021-02-08 | ABERNETHY MATT Chief Financial Officer | Grant or award · Stock Option | +49,049 | 49,049 | ||
| 2021-02-08 | Gano Kyle Chief Business Development Off | Sale | −1,070 | $116.89 | $125K | 102,406 |
| 2021-02-08 | Gano Kyle Chief Business Development Off | Sale | −1,000 | $116.83 | $117K | 103,306 |
| 2021-02-08 | Gano Kyle Chief Business Development Off | Sale | −1,623 | $116.83 | $190K | 104,768 |
| 2021-02-08 | Gano Kyle Chief Business Development Off | Grant or award · Stock Option | +44,632 | 44,632 | ||
| 2021-02-08 | Gano Kyle Chief Business Development Off | Grant or award · Restricted Stock Unit | +7,439 | 7,439 | ||
| 2021-02-08 | ABERNETHY MATT Chief Financial Officer | Sale | −880 | $116.85 | $103K | 13,043 |
| 2021-02-08 | ABERNETHY MATT Chief Financial Officer | Sale | −2,030 | $116.81 | $237K | 14,869 |
| 2021-02-08 | ABERNETHY MATT Chief Financial Officer | Grant or award · Stock Option | +44,632 | 44,632 | ||
| 2021-02-08 | ABERNETHY MATT Chief Financial Officer | Grant or award · Restricted Stock Unit | +7,439 | 7,439 |
Page 59 of 62 · 1,221 trades